DIA Biosimilars 2013

AtheroNova

AtheroNova initiates phase I clinical trial of AHRO-001

Wednesday, July 3, 2013 08:54 AM

AtheroNova, a biotech company focused on the R&D of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, has initiated a phase I clinical trial with its compound, AHRO-001, to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with licensing partner OOO CardioNova.

More... »

Cenduit: Now with Patient Reminders

AtheroNova names Shaw as new clinical affairs officer

Thursday, January 10, 2013 08:00 AM

AtheroNova, a biotech company focused on compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, has appointed Joan E. Shaw, MT (ASCP), SCC as senior director of clinical operations.

More... »

CRF Health – eCOA Forum

Frontage to develop AtheroNova clinical trial supplies

Friday, April 27, 2012 11:59 AM

Frontage, a global CRO based in Ecton, Penn., has signed an agreement to develop clinical trial supplies with AtheroNova, a biotech company focused on R&D of compounds to regress atherosclerotic plaque.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs